SCHEMBL4220932

SCHEMBL4220932

CC(=O)c1ccc(OCCOc2c(-c3ccc(F)cc3)n(C)c3ccccc3c2=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAOB P27338 1/20 0.43
HPGD P15428 4/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HSD17B10 Q99714 3/20 0.41
KMT2A Q03164 2/20 0.41
USP2 O75604 1/20 0.41
BRD4 O60885 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTR5A P47898 2/20 0.40
WDR5 P61964 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5048604 0.97 HTT (0.45) HTTSMN1; SMN2MAOBHPGDKDM4E
SCHEMBL14011598 0.91 HTT (0.47) HTTSMN1; SMN2MAOBHPGDKDM4E
SCHEMBL4212761 0.90 SMN1; SMN2 (0.46) HTTSMN1; SMN2MAOBHPGDKDM4E
SCHEMBL4216145 0.90 MAOB (0.43) HTTSMN1; SMN2MAOBALDH1A1MAPT
SCHEMBL5044605 0.90 THRB (0.43) HTTSMN1; SMN2MAOBALDH1A1MAPT
SCHEMBL4218108 0.89 HTT (0.44) HTTSMN1; SMN2MAOBHPGDKDM4E
SCHEMBL4210000 0.88 SMN1; SMN2 (0.42) HTTSMN1; SMN2MAOBHPGDKDM4E
SCHEMBL4208245 0.87 BRD4 (0.42) SMN1; SMN2HPGDKDM4EALDH1A1HSD17B10
SCHEMBL5046042 0.87 BRD4 (0.43) HTTHSD17B10BRD4NPSR1L3MBTL1
SCHEMBL4218634 0.87 MAOB (0.40) MAOBL3MBTL1HTR5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1678157-A4 HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF REDDY US THERAPEUTICS INC (US) 2009-03-18 EP disclosed
US-7456288-B2 Heterocyclic compounds and methods of making and using thereof REDDY US THERAPEUTICS, INC. (US) 2008-11-25 US disclosed
EP-1678157-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF Reddy US Therapeutics, Inc. (US) 2006-07-12 EP disclosed
US-20050119269-A1 Heterocyclic compounds and methods of making and using thereof DR. REDDY'S LABORATORIES LTD. (IN) 2005-06-02 US disclosed
WO-2005042712-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF REDDY US THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119269-A1 Heterocyclic compounds and methods of making and using thereof PYGM, MYLK, HMOX1 HTT 2969/4885SMN1; SMN2 1448/4885MAOB 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.